Metasyn taps Webb as new CEO

Article

Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.

Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.

Webb comes to Metasyn from Ciba-Corning Diagnostics, wherehe was senior vice president of worldwide marketing and strategicplanning.

The appointment of Webb represents a step in the company'seffort to commercialize its products, which are in advanced preclinicalstudies, according to the firm. Metasyn is developing MS-323,an MRI blood-pool agent that binds reversibly to albumin.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.